Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 17/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | HTR6 | P50406 | 8/20 | 0.61 |
| ▸ | HTR2A | P28223 | 7/20 | 0.61 |
| ▸ | DRD2 | P14416 | 5/20 | 0.61 |
| ▸ | HTR1A | P08908 | 3/20 | 0.59 |
| ▸ | HTR2C | P28335 | 3/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | CCR1 | P32246 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25758471 | 0.93 | HTR7 (0.60) | HTR7POLBHTR6HTR2ADRD2 | |
| SCHEMBL24069065 | 0.85 | HTR7 (0.56) | HTR7POLBHTR1A | |
| SCHEMBL25289791 | 0.85 | HTR7 (0.73) | HTR7POLBHTR6HTR2ADRD2 | |
| SCHEMBL6338842 | 0.85 | POLB (0.80) | HTR7POLBHTR6HTR2ADRD2 | |
| SCHEMBL7461210 | 0.84 | HTR7 (0.50) | HTR7POLBHTR6HTR2ADRD2 | |
| SCHEMBL24069061 | 0.82 | HTR7 (1.00) | HTR7POLBHTR6HTR2ADRD2 | |
| SCHEMBL10194535 | 0.81 | POLB (0.74) | HTR7POLBHTR6HTR2ADRD2 | |
| SCHEMBL6341348 | 0.81 | POLB (0.74) | HTR7POLBHTR6HTR2ADRD2 | |
| SCHEMBL25759707 | 0.81 | BCHE (0.63) | HTR7HTR6HTR2ADRD2HTR1A | |
| SCHEMBL24069060 | 0.81 | BCHE (0.50) | HTR7POLBHTR6HTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | SLC6A2, SLC6A3, SLC6A4 | HTR7 79/4885POLB 3203/4885HTR6 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.